Supply-demand and market price fluctuation risk for feed-grade amino acids
First written in FY2016. 16 of 26 entries say "Materialised", first in FY2017-Q1. Latest entry: FY2025-H1.
No other company in this theme has enough history to compare yet.
- FY2025-H1RestatedAnnual report
「No new business or other risks arose during the six months ended 30 June. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The disclosure states that there were no new developments or significant changes regarding supply and demand and market fluctuation risks for feed-grade amino acids. - FY2024-Q2RestatedAnnual report
「No new business or other risks arose during the cumulative second-quarter period. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The disclosure states that there were no new developments or significant changes regarding supply and demand and market fluctuation risks for feed-grade amino acids. - FY2024-Q1RestatedAnnual report
「There were no newly arising business or other risks during the first quarter of the current consolidated cumulative period. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The disclosure states that there were no new developments or significant changes regarding supply and demand and market fluctuation risks for feed-grade amino acids. - FY2023-Q1First-quarter results updatedAnnual report
「Although structural reform in Animal Nutrition had an impact, Other remained on par with the previous year due to increased sales of Medical Foods, Sports Nutrition and other products.」
Although the effects of structural reform remained in Animal Nutrition, revenue for Other overall was on par with the previous year due to increased sales of Medical Foods and other products. - FY2022-Q3Revenue decline and earnings improvement from structural reformAnnual report
「Other recorded a decline in revenue due to lower sales volume in Animal Nutrition, lower demand for Sports Nutrition and other factors. Other recorded a substantial increase in profit due to lower costs and other factors resulting from structural reform in Animal Nutrition.」
Although lower sales volume and other factors continued to weigh on revenue in Animal Nutrition, lower costs and other factors resulting from structural reform led to a substantial increase in profit. - FY2022-Q2Revenue decline and earnings improvement from structural reformAnnual report
「Other recorded a decline in revenue due to lower sales volume in Animal Nutrition, lower demand for Sports Nutrition and other factors. Other recorded a substantial increase in profit due to lower costs and other factors resulting from structural reform in Animal Nutrition.」
Although lower sales volume and other factors continued to weigh on revenue in Animal Nutrition, lower costs and other factors resulting from structural reform led to a substantial increase in profit. - FY2021MaterialisedAnnual report
「The carrying amounts of the feed-grade amino acid manufacturing facilities in Europe and North America were reduced to their recoverable amounts, and impairment losses of ¥7,775 million and ¥7,960 million, respectively, were recorded under Other operating expenses.」
Although lower sales volumes continued to affect Animal Nutrition, impairment losses totaling ¥15.735 billion were recorded for the facilities in Europe and North America, showing the actual loss from structural reform measures in response to deteriorating supply and demand and market conditions. - FY2021-Q3Third-quarter results updatedAnnual report
「Other recorded a decline in revenue due to lower sales volume in Animal Nutrition, lower demand for Sports Nutrition and other factors. Other recorded a substantial increase in profit, mainly due to higher selling prices in Animal Nutrition.」
Although lower sales volume and other factors continued to weigh on revenue in Animal Nutrition, higher selling prices resulted in a substantial increase in profit. This represents a different outcome from the previous deterioration centered on lower unit prices. - FY2021-Q2Second-quarter results updatedAnnual report
「Other recorded a decline in revenue due to lower sales volume in Animal Nutrition, lower demand for Sports Nutrition and other factors. Other recorded a substantial increase in profit due to higher selling prices and other factors in Animal Nutrition.」
Although lower sales volume and other factors continued to weigh on revenue in Animal Nutrition, higher selling prices and other factors resulted in a substantial increase in profit, producing a different outcome from the previous deterioration in results centered on lower unit prices. - FY2021-Q1Earnings improvement from higher selling pricesAnnual report
「Other recorded a substantial decline in revenue, mainly due to lower sales volume in Animal Nutrition and lower demand for Sports Nutrition. Other recorded a substantial increase in profit in Animal Nutrition, mainly due to higher selling prices and other factors.」
Although lower sales volume continued to weigh on revenue in Animal Nutrition, higher selling prices and other factors resulted in a substantial increase in profit, producing a different outcome from the previous deterioration in results centered on lower unit prices. - FY2020MaterialisedAnnual report
「Animal Nutrition recorded a substantial decline in revenue due to lower demand and selling prices resulting from the global spread of African swine fever.」
Lower demand and selling prices resulting from the global spread of African swine fever affected full-year results, and Animal Nutrition revenue was ¥56.6 billion, representing a substantial decline from the previous fiscal year. - FY2020-Q3MaterialisedAnnual report
「Animal Nutrition recorded a substantial decline in revenue due to lower demand and selling prices resulting from the global spread of African swine fever.」
Lower demand and selling prices resulting from the global spread of African swine fever also materialized as a substantial decline in revenue in the Animal Nutrition business during the 9-month period. - FY2020-Q2MaterialisedAnnual report
「Animal Nutrition recorded a substantial decline in revenue due to lower demand and selling prices resulting from the global spread of African swine fever.」
Lower demand and selling prices resulting from the global spread of African swine fever continued to materialize as a substantial decline in revenue in the Animal Nutrition business. - FY2020-Q1MaterialisedAnnual report
「Animal Nutrition recorded a substantial decline in revenue due to the spread of African swine fever and other factors.」
The spread of African swine fever was newly identified as a factor behind the substantial decline in revenue in the Animal Nutrition business, which handles feed-grade amino acids, bringing supply, demand and demand fluctuation risks to the fore. - FY2019MaterialisedAnnual report
「Animal Nutrition recorded a substantial decline in profit, mainly due to the lower unit price of tryptophan.」
Fluctuations in market conditions and unit prices for feed-grade amino acids appeared in full-year results as a substantial decline in profit caused by the lower unit price of tryptophan. - FY2019-Q3MaterialisedAnnual report
「In Animal Nutrition, tryptophan recorded a substantial increase in revenue due to higher sales volume, while threonine and lysine recorded declines in revenue due to lower sales volumes, resulting in a decline in revenue overall.」
Sales volumes of feed-grade amino acids continued to fluctuate by product, with lower volumes of threonine and lysine contributing to the decline in revenue for Animal Nutrition overall. - FY2019-Q2MaterialisedAnnual report
「In Animal Nutrition, tryptophan recorded a substantial increase in revenue, but lower sales volumes of lysine and threonine resulted in a decline in revenue overall.」
Sales volumes and revenue for feed-grade amino acids continued to fluctuate by product, with lower volumes of lysine and threonine contributing to the decline in revenue for Animal Nutrition overall. - FY2019-Q1MaterialisedAnnual report
「In Animal Nutrition, tryptophan recorded a substantial increase in revenue, while lysine and threonine recorded declines in revenue mainly due to lower sales volumes, leaving the business overall on par with the previous year.」
Item-by-item fluctuations in feed-grade amino acid volumes and sales continued, with lower sales volumes of lysine and threonine contributing to the decline in revenue. - FY2018-Q3MaterialisedAnnual report
「Although affected by foreign exchange rates, lysine and threonine achieved results on par with the same period of the previous year because sales volumes were lower. Tryptophan recorded a substantial increase in revenue because both sales volume and selling price were substantially higher. Specialty products such as AjiPro®-L recorded a substantial increase in revenue.」
Fluctuations in feed-grade amino acid volumes and prices continued to affect results for the 9-month period. Lysine and threonine saw lower volumes, while tryptophan and specialty products recorded substantial increases in revenue. - FY2018-Q2MaterialisedAnnual report
「Lysine and threonine recorded declines in revenue because sales volumes were below those of the same period of the previous year. Tryptophan recorded a substantial increase in revenue because both sales volume and selling price were substantially higher. Specialty products such as valine also recorded a substantial increase in revenue.」
Fluctuations in feed-grade amino acid volumes and prices continued to affect half-year results. Lysine and threonine saw lower volumes, while tryptophan and specialty products recorded increases in revenue. - FY2018-Q1MaterialisedAnnual report
「Lysine recorded a decline in revenue because sales volume was below that of the same period of the previous year. Threonine recorded a decline in revenue because sales volume was substantially lower. Tryptophan recorded a substantial increase in revenue because both sales volume and selling price were substantially higher. Specialty products such as valine also recorded a substantial increase in revenue.」
Risks from fluctuations in feed-grade amino acid volumes and prices continued to affect results. Lysine and threonine saw lower volumes, while tryptophan and specialty products recorded increases in revenue. - FY2017MaterialisedAnnual report
「Threonine recorded a substantial decline in revenue because, although sales volume exceeded that of the previous fiscal year, selling price was substantially lower. Tryptophan recorded a decline in revenue because, although sales volume was substantially higher, selling price was substantially lower. Specialty products such as valine recorded an increase in revenue.」
While market risk, centered on lower prices for feed-grade amino acids, materialized as a substantial full-year decline in revenue and profit in the Animal Nutrition business, specialty products recorded an increase in revenue. - FY2017-Q3MaterialisedAnnual report
「Lysine recorded a substantial decline in revenue because both sales volume and selling price were below the same period of the previous year. Threonine's sales volume exceeded that of the same period of the previous year, and tryptophan's sales volume was substantially higher, but both recorded substantial declines in revenue because selling prices were substantially lower. Specialty products such as valine recorded an increase in revenue.」
Supply and demand and market fluctuations, centered on lower selling prices for feed-grade amino acids, continued to materialize as a substantial decline in revenue and profit in Animal Nutrition for the 9-month period. Specialty products such as valine, however, recorded an increase in revenue. - FY2017-Q2MaterialisedAnnual report
「Lysine recorded a substantial decline in revenue because both sales volume and selling price were below the same period of the previous year. Threonine's sales volume exceeded that of the same period of the previous year, and tryptophan's sales volume was substantially higher, but both recorded substantial declines in revenue because selling prices were substantially lower. Specialty products such as valine also recorded a decline in revenue.」
Supply and demand and market fluctuations, centered on lower selling prices for feed-grade amino acids, have materialized as a substantial half-year decline in revenue and profit in Animal Nutrition. - FY2017-Q1MaterialisedAnnual report
「Lysine recorded a substantial decline in revenue because both sales volume and selling price were below the same period of the previous year. Threonine and tryptophan also recorded substantial declines in revenue because, although sales volumes exceeded those of the same period of the previous year, selling prices were substantially lower.」
The decline in feed-grade amino acid volumes and prices has materialized as a substantial decline in revenue and profit in the Animal Nutrition business this quarter. - FY2016First statedAnnual report
「The selling prices of the feed-grade amino acids handled by our Group in the Life Support business tend to fluctuate depending on grain market conditions and supply and demand trends for feed-grade amino acids.」
The period saw lower sales volumes and prices for lysine, threonine and tryptophan, as well as lower profit in the Animal Nutrition business. An impairment loss of ¥3,316 million was recorded for the Thailand facilities.